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ABSTRACT 
The reaction of exocyclic enaminones namely, 2-(dimethylaminomethylene)-3,4-dihydro-2H-naphthalen-1-one,  3-
(dimethylaminomethylene)-thiochroman-4-one and 2-(dimethyl-aminomethylene)-indane-1,3-dione, each with heterocyclic 
diazonium salts afforded the respective hydrazones which undergo either in situ dehydrative cyclization or cyclized by 
heating with acetic acid to give polycyclic compounds. The structure of all the newly synthesized products were confirmed 
by elemental and spectral (IR, 
I
H NMR, Mass) data. Also, the biological activity of some of the prepared compounds was 
tested against some microorganisms and promising results were obtained. 
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INTRODUCTION  
Literature reports indicate that enaminones constitute an important class of useful precursors in organic synthesis, in 
pharmaceutical development and in heterocyclic synthesis [1-6]. Since enaminones have two reactive sites, they are able 
to react with both electrophiles and nucleophiles [7-11] to give a variety of bioactive products. Several reports indicate that 
reaction of acyclic enaminones as nucleophiles with heterocyclic diazonium salts give the azo compounds which undergo 
in situ cyclization via elimination of dimethylamine to give the respective cyclized products [12,13] (Scheme 1). On the 
other hand, literature survey indicate that only one report [14] was found about reaction of exocyclic enaminones with 
heterocyclic diazonium salts.  
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Scheme 1 
 
On the basis of these findings, we report herein a facile method for synthesizing tetra- and penta-heterocyclic ring systems 
via coupling reaction of a number of different exocyclic enaminones with heterocyclic diazonium salts. Our objective from 
this study is to investigate the reactivity of these exocyclic enaminones towards a variety of heterocyclic diazonium salts. 
Also, the activity of the products obtained from this reaction against a number of  bacteria and fungi species was studied.  
Experimental  
Materials  
Melting points were determined on an electrothermal Gallenkamp apparatus and are uncorrected. The IR spectra were 
recorded in potassium bromide using Pye Unicam SP-1000 spectrophotometer. 
1
HNMR spectra were recorded in DMSO-
d6 using a varian Em-300 MHz Spectrometer and TMS as internal reference. Mass spectra were recorded on AEIMS30 
mass spectrometer operating at 70ev. Elemental analyses were carried out by the Microanalytical Center of Cairo 
University, Giza, Egypt. Antimicrobial activity was carried out at the Regional Center for Mycology and Biotechnology 
(RCMB) at Al-Azhar University, Cairo, Egypt. The enaminones 4a,b and 5 were reported as described before [15-17]. 
Coupling of the enaminones 4a,b and 5 with heterocyclic amines  
General procedure: To a stirred solution of the appropriate enaminones 4a,b or 5 (10 mmol) in ethanol (50 ml) was added 
sodium hydroxide (0.4 g, 10 mmol) and the mixture was cooled in an ice bath to 0–5 ºC. To the resulting solution, while 
being stirred, was added dropwise over a period of 20 min a solution of the appropriate heterocyclic diazonium salt, 
prepared as usual by diazotizing the respective heterocyclic amine (2-amino-[1,2,4]-triazole, 2-amino-benzimidazole or 5-
amino-3-phenyl-pyrazole) (10 mmol) in hydrochloric acid (6 M, 6 ml) or in nitric acid with sodium nitrite (1 M, 10 ml). The 
whole mixture was then left in a refrigerator overnight. The precipitated solid formed was collected, washed with water and 
finally crystallized from ethanol to give the respective hydrazone 8b, 12b, 14, 16, 18 or the cyclized compounds 9a, 11a,b 
and 12a,  respectively. 
Cyclization of hydrazones 8b, 12b, 14, 16 and 18 
A solution of hydrazones 8b, 12b, 14, 16 or 18 (1 mmole) in glacial acetic acid (10 mL) was refluxed for 15 h. After 
cooling, the solution was then poured into ice and sodium acetate and the precipitate formed was filtered off and 
crystallized from the appropriate solvent to give compounds 9b, 13b, 15, 17 and 19, respectively. 
3-[(2H-[1,2,4]Triazol-3-yl)-hydrazono]-thiochroman-4-one (8b) 
Yellow solid, (81% yield), mp 210-212ºC (EtOH); IR (KBr) νmax 3330, 3237 (2NH), 1668 (CO), 1567 (C=N), 
1
H NMR 
(DMSO-d6) δ 5.48 (s, 2H, CH2), 7.54-8.56 (m, 4H, ArH), 8.88 (s, 1H, triazole-H), 12.21 (s, 1H, NH), 14.0 (s, 1H, NH). MS 
m/z (%) 259 (M
+
, 54), 258 (29), 177 (86), 176 (34), 149 (35), 136 (59), 84 (100), 76 (33), 57 (59). Anal. Calcd. For 
C11H9N5OS (259.29): C, 50.95; H, 3.50; N, 27.01. Found: C, 50.78; H, 3.37; N, 26.94%. 
6,7-Dihydro-1,3,4,5,11c-pentaaza-cyclopenta[c]phenanthrene (9a) 
Redish brown powder, (70% yield), mp 72-74 ºC (EtOH / Dioxane); IR (KBr) νmax 1632 (C=N), 
1
H NMR (DMSO-d6) δ 3.10 
(t, J = 7 Hz, 2H, CH2), 3.29 (t, J = 7 Hz, 2H, CH2), 7.23-7.78 (m, 4H, ArH), 8.31 (s, 1H, triazole-H). MS m/z (%) 224 (M
+
+1, 
45), 223 (M
+
, 19), 222 (26), 115 (52), 63 (100). Anal. Calcd. For C12H9N5 (223.23): C, 64.56; H, 4.06; N, 31.37. Found: C, 
64.35; H, 4.19; N, 31.26%. 
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6H-7-Thia-1,3,4,5,11c-pentaaza-cyclopenta[c]phenanthrene (9b) 
Dark brown crystals, (67% yield), mp 150-152 ºC (EtOH); IR (KBr) νmax 1564 (C=N), 
1
H NMR (DMSO-d6) δ 4.25 (s, 2H, 
CH2), 7.29-7.90 (m, 4H, ArH), 9.25 (s, 1H, triazole-H). MS m/z (%) 242 (M
+
+1, 61), 241 (M
+
, 64), 240 (62), 237 (55), 236 
(52), 233 (55), 221 (54), 218 (54), 180 (60), 162 (87), 136 (75), 108 (85), 76 (100). Anal. Calcd. for C11H7N5S (241.27): C, 
54.76; H, 2.92; N, 29.03. Found: C, 54.57; H, 2.86; N, 29.11%. 
2-Phenyl-6,7-dihydro-1,4,5,11c-tetraaza-cyclopenta[c]phenanthrene (11a) 
Orange solid, (77% yield), mp 210-212 ºC (EtOH/Dioxane); IR (KBr) νmax 1630 (C=N), 
1
H NMR (DMSO-d6) δ 3.14 (t, J = 7 
Hz, 2H, CH2), 3.41 (t, J = 7 Hz,2H, CH2), 7.50-7.54 (m, 5H, ArH), 7.55-7.89 (m, 4H, ArH), 7.89 (s, 1H, pyrazole-H). MS m/z 
(%) 298 (M
+
, 100), 297 (36), 154 (49), 77 (57). Anal. Calcd. for C19H14N4 (298.34): C, 76.49; H, 4.73; N, 18.78. Found: C, 
76.30; H, 4.67; N, 18.58%. 
2-Phenyl-6H-7-thia-1,4,5,11c-tetraaza-cyclopenta[c]phenanthrene (11b) 
Brown powder, (70% yield), mp 130-132 ºC (Dioxane); IR (KBr) νmax 1590(C=N), 
1
H NMR (DMSO-d6) δ 4.57 (s, 2H, CH2), 
7.40-8.22 (m, 9H, ArH), 7.98 (s, 1H, pyrazole-H ). MS m/z (%) 316 (M
+
, 36), 315 (18), 185 (32), 155 (16), 145 (21), 101 
(19), 77 (42). Anal. Calcd. For C18H12N4S (316.38): C, 68.33; H, 3.82; N, 17.71. Found: C, 68.24; H, 3.66; N, 17.59%. 
3-[(1H-Benzimidazol-2-yl)-hydrazono]-thiochroman-4-one (12b) 
Brown powder, (77% yield), mp 136-138 ºC (EtOH/Dioxane); IR (KBr) νmax 3377, 3114 (2NH), 1680 (CO), 1593 (C=N). 
1
H 
NMR (DMSO-d6) δ 4.29 (s, 2H, CH2), 7.16-7.97 (m, 8H, ArH), 10.19 (s, 1H, NH), 12.82 (s, 1H, NH). MS m/z (%) 308 (M
+
, 
0.3), 133 (100), 132 (23), 77 (5). Anal. Calcd. For C16H12N4OS (308.36): C, 62.32; H, 3.92; N, 18.17. Found: C, 62.18; H, 
3.78; N, 18.01%. 
5,6-Dihydro-7,8,9,13b-tetraaza-indeno[2,1-c]phenanthrene (13a) 
Brown powder, (70% yield), mp 270ºC (EtOH/Dioxane); IR (KBr) νmax1634 (C=N), 
1
H NMR (DMSO-d6) δ 2.72 (t, 2H, CH2), 
3.14 (t, 2H, CH2), 7.25-7.59 (m, 8H, ArH). MS m/z (%) 272 (M
+
, 30), 253 (29), 214 (23), 149 (43), 58 (100). Anal. Calcd. 
For C17H12N4 (272.30): C, 74.98; H, 4.44; N, 20.58. Found: C, 74.85; H, 4.21; N, 20.34 %. 
6H-5-Thia-7,8,9,13b-tetraaza-indeno[2,1-c]phenanthrene (13b) 
Reddish brown powder (72% yield), mp 60-62 ºC (EtOH); IR (KBr) νmax 1584 (C=N). 
1
H NMR (DMSO-d6) δ 5.57 (s, 2H, 
CH2), 7.60-8.48 (m, 8H, ArH). MS m/z (%) 290 (M
+
, 2), 213 (13), 158 (42), 117 (12), 102 (100), 77 (32). Anal. Calcd. for 
C16H10N4S (290.34): C, 66.19; H, 3.47; N, 19.30. Found: C, 66.05; H, 3.28; N, 19.11%. 
2-[(5-Phenyl-2H-pyrazol-3-yl)-hydrazono]-indan-1,3-dione (14) 
Orange crystal, (65% yield), mp 120-122 ºC (EtOH); IR (KBr) νmax 3390 (NH), 3151 (NH), 1713 (CO), 1670 (CO), 1593 
(C=N). 
1
H NMR (DMSO-d6) δ 7.37-7.86 (m, 9H, ArH), 7.90 (s, 1H, pyrazole-H), 13.34 (s, 2H, 2NH). MS m/z (%) 317 
(M
+
+1, 38), 316 (54), 285 (40), 228 (48), 149 (100), 107 (40), 57 (80). Anal. Calcd. For C18H12N4O2 (316.31): C, 68.35; H, 
3.82; N, 17.71. Found: C, 68.20; H, 3.65; N, 17.53%. 
2-Phenyl-1,4,5,10c-tetraaza-cyclopenta[c]fluoren-6-one (15) 
Brown powder, (61% yield), mp 158-160 ºC (EtOH); IR (KBr) νmax 1726 (CO). 
1
H NMR (DMSO-d6) δ 7.57-8.59 (m, 9H, 
ArH), 8.19 (s, 1H, pyrazole-H). MS m/z (%) 299 (M
+
+1, 48), 298 (92), 251 (62), 195 (50), 167 (56), 77 (100), 76 (78). Anal. 
Calcd. For C18H10N4O (298.30): C, 72.48; H, 3.38; N, 18.78. Found: C, 72.27; H, 3.23; N, 18.56%. 
2-[(2H-[1,2,4]Triazol-3-yl)-hydrazono]-indan-1,3-dione (16) 
Yellow powder, (65% yield), mp 274-276 ºC (EtOH/Dioxane); IR (KBr) νmax 3116 (NH), 1718, 1679 (CO), 1531 (C=N). 
1
H 
NMR (DMSO-d6) δ 7.42-8.12 (m, 4H, ArH), 8.51 (s, 1H, Triazole-H), 13.07 (s, 1H, NH), 14.15 (s, 1H, NH). MS m/z (%) 242 
(M
+
, 13), 241 (30), 158 (61), 105 (25), 102 (100) ,76 (79), 75 (56). Anal. Calcd. For C11H7N5O2 (242.21): C, 54.77; H, 2.93; 
N, 29.03. Found: C, 54.54; H, 2.68; N, 28.89%. 
1,3,4,5,10c-Pentaaza-cyclopenta[c]fluoren-6-one (17) 
Yellow powder, (60% yield), mp 290-292 ºC (EtOH/Dioxane); IR (KBr) νmax 1719 (CO), 1533 (C=N). 
1
H NMR (DMSO-d6) δ 
7.15-7.99 (s, 4H, ArH), 8.64 (s, 1H, triazole-H). MS m/z (%) 224 (M
+
+1, 7), 223 (51), 158 (32), 114 (43), 102 (77), 79 
(100), 75 (33). Anal. Calcd. For C11H5N5O (223.19): C, 59.20; H, 2.26; N, 31.38. Found: C, 59.07; H, 2.13; N, 31.16%. 
2-[(1H-Benzimidazol-2-yl)-hydrazono]-indan-1,3-dione (18) 
Yellow crystal (68% yield), mp > 300 ºC (Dioxane); IR (KBr) νmax; 3412, 3254 (2NH), 1715, 1690 (2CO), 1524 (C=N). 
1
H 
NMR (DMSO-d6) δ 7.10-7.89 (m, 8H, ArH), 9.28 (s, 1H, NH), 10.57 (s, 1H, NH). MS m/z (%) 291 (M
+
+1, 26), 290 (36), 272 
(43), 188 (42), 149 (73), 136 (41), 71 (55), 58 (100), 57 (78). Anal. Calcd. for C16H10N4O2 (290.28): C, 66.20; H, 3.47; N, 
19.30. Found: C, 66.05; H, 3.24; N, 19.16%. 
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5,6,7,12c-Tetraaza-indeno[2,1-c]fluoren-8-one (19) 
Brown crystal, (65% yield), mp 152ºC (EtOH); IR (KBr) νmax 1720 (CO), 1534 (C=N). 
1
H NMR (DMSO-d6) δ 6.98-7.59 (m, 
8H, ArH). MS m/z (%) 273 (M
+
+1, 18), 191(20), 160 (20), 127 (20), 98 (21), 80 (100), 76 (19). Anal. Calcd. For C16H8N4O 
(272.26): C, 70.58; H, 2.96; N, 20.58. Found: C, 70.31; H, 2.78; N, 20.34%. 
 
Microorganism's strains and preparation of inoculum: A. Fumigatus (RCMB 02568), S. Racemosum (RCMB 05922), G. 
Candidum (RCMB 05097), C. Albicans (RCMB 05036), S. Pneumoniae (RCMB 010010), B. Subtilis (RCMB 010067), P. 
Aeruginosa (RCMB 010043) and E. Coli (RCMB 010052). strains were used in this study. The microbial suspension 
equivalent to the turbidity of 0.5 McFarland (10
8
 CFU/ml) standard was prepared from a fresh subculture of tested bacteria 
in Mueller Hinton Broth (MHB) and tested fungi in Sabouraud dextrose Broth (SDB) then this suspension was diluted to 
10
6
 CFU/ml using MHB for bacteria and Sabouraud dextrose Broth (SDB) for tested fungi. The adjusted microbial 
inoculum (100 μl) were added to each well of sterile 96-well flat-bottomed microtiter plate containing the tested 
concentration of tested samples (100 μl/well). As a result, last inoculum concentration of 5×10
5 
CFU/ml was obtained in 
each well. Three wells containing microbial suspension with no sample using DMSO employed for dissolving the tested 
compound (Growth control) and two wells containing only media (background control) were included in this plate. Optical 
densities were measured after 24 hours at 37°C for bacteria and after 48 hours at 28°C for fungi using a multi-detection 
microplate reader at The Regional Center for Mycology and Biotechnology (Sun Rise –Tecan,  USA) at 600 nm. Ampicillin, 
Gentamicin and Amphotericin B were used as standards for Gram positive bacteria, Gram negative bacteria and fungi 
respectively. 
For the determination of MIC of tested samples by the micro-broth kinetic assay, the percentage of growth at each 
sample concentration was calculated with the following equation: % growth = [(OD600 of wells containing the 
sample/OD600 of the sample-free well) x 100] after substraction of background ODs (ODs of microorganism-free 
wells)[18].  
Results and discussion  
The starting exocyclic enaminones 4a,b and 5 were prepared in good yields as described before [15-17] via condensation 
of the corresponding cyclic ketones namely, tetralone, 4-thiochromanone or indane-1,3-dione, with dimethylformamide-
dimethylacetal (DMF-DMA) in dry xylene (or toluene) under reflux for 6hrs. The reaction of enaminones 4a,b each with a 
variety of diazonium salts of heterocyclic amines, namely, 3-amino-1,2,4-triazole, 2-aminobenzimidazole and 5-amino-3-
phenyl-1H-pyrazole, was then investigated. Thus, reaction of enaminones 4a,b, each with the diazonium salt of 3-amino-
1,2,4-triazole at low temperature in ethanol and in the presence of sodium acetate afforded products 8b and 9a                                   
(Scheme 2). The structure assigned for the products 8b and 9a was confirmed based on elemental and spectral (IR, 
1
HNMR and Mass) data (see Experimental). For example, the IR spectra for product 9a revealed the absence of both the 
carbonyl and the N-H stretching bands. Also, ¹H NMR displayed only singlet signal at δ  9.25 ppm and multiplet signals in 
the region δ 7.29-7.90 ppm due to the triazole and aromatic protons, respectively. The mass spectra of 8a and 9b 
revealed in each case a molecular ion peak which is in agreement with the assigned structure. Based on the foregoing 
data, we can conclude that product 9b were formed directly via in situ dehydrative cyclization of the respective hydrazone 
8b (Scheme 2).  
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Scheme 2 
 
Similarly, coupling reaction of 4a-b each with the diazonium salt of 3-amino-5-phenyl-pyrazole or 2-aminobenzimidazole 
under the same reaction conditions afforded the respective pentacyclic products 11a,b, 13a and the hydrazone 12b. The 
structure of the products was also identified on the basis of both elemental and spectral data (see Experimental). 
Treatment of the hydrazones 8b and 12b each with glacial acetic acid under reflux for 15hrs, gave the respective 
polycyclic compounds 9b and 13b (Scheme 2 and 3). 
The structure assigned for the cyclized products 9b and 13b was established through the data obtained from both 
elemental and spectral analysis. For example, the IR spectrum of products revealed the absence of the characteristic 
bands due to the N-H groups. Also, the 
1
H NMR spectrum of the same products displayed the expected peaks assigned 
for the aromatic protons and revealed the absence of the peaks attributed to the 2N-H protons. 
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On the other hand, coupling reaction of exocyclic enaminone 5 with the same heterocyclic diazonium salts under the 
above mentioned conditions led to formation of the stable hydrazones 14, 16 and 18, which in turn cyclized by elimination 
of one molecule of water via heating with glacial acetic acid to give the final polycyclized products (Scheme 4). 
The structure of the hydrazones 14, 16 and 18 was also confirmed based on the data obtained from elemental and 
spectral analysis (see Experimental). 
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Scheme 4 
Biological Screening : 
Anti-microbial activity: 
In vitro anti-microbial screening of some of the newly prepared compounds was carried out using four fungal strains , 
namely , Aspergillus fumigatus ( RCMB 02568)(AF), Syncephalastrum racemosum (RCMB 05922)(SR), Geotricum 
candidum (RCMB 05097)(GC) and Candida albicans (RCMB 05036)(CA) and four bacteria species including Gram 
positive bacteria, Streptococcus pneumoniae (RCMB 010010)(SP), Bacillus subtilis (RCMB 010067)(BS), Gram negative 
bacteria, Pseudomonas aeruginosa (RCMB 010043)(PA) and Escherichia coli (RCMB10052)(EC). The results obtained 
showed that all the tested compounds especially compound 14 displayed high activity against most of the used 
microorganisms (fungi and bacteria) (see Table 1).The products 12b and 16 have no activity against Candida albicans 
(CA). Also, the latter products together with products 8b and 11b have no activity against Pseudomonas aeruginosa (PA). 
Compound 14 showed higher potency against the fungus, namely, Syncephalastrum racemosum (SR) than the standard 
fungicide Amphotericin B (see Table 1) 
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Table 1.  Preliminary anti-microbial activity for tested compounds 
Compd  
No.  
Fungi Gram positive 
bacteria  
Gram negative 
bacteria  
A.  
fumigat
us  
S.  
racemosu
m  
G.  
candidu
m  
Candida  
albicans  
S. 
Pneumoni
ae  
B.  
subtilis  
P. 
aeruginos
a  
E. coli  
8b  14.2 
(±0.44) 
15.3 
(±0.58) 
18.9 
(±0.14) 
16.2 
(±0.25) 
16.2 
(±0.15) 
19.8 
(±0.42) 
N.A. 15.9 
(±0.37) 
11b 16.1 
(±0.33) 
17.2 
(±0.25) 
19.4 
(±0.34) 
18.2 
(±0.24) 
17.3 
(±0.63) 
20.2 
(±0.44) 
N.A. 17.4 
(±0.53) 
12b 13.2 
(±0.33)  
14.1 
(±0.25) 
14.9 
(±0.34)  
N.A.   14.3 
 (±0.15)  
15.2 
(±0.42) 
N.A. 12.4 
(±0.53) 
14  20.3 
(±0.25) 
22.4 
(±0.44) 
22.6 
(±0.63) 
19.4 
(±0.58) 
21.4 
(±0.25) 
22.4 
(±0.63) 
12.6 
(±0.44) 
18.6 
(±0.44) 
16  10.6 
(±0.25) 
11.7 
(±0.34) 
16.5 
(±0.58) 
N.A.   16.0 
(±0.44) 
18.3 
(±0.67) 
N.A. 13.0 
(±0.46) 
18  16.3 
(±0.44) 
18.4 
(±0.58) 
19.1 
(±0.37) 
15.2 
(±0.58) 
18.9 
(±0.44) 
20.3 
(±0.58) 
10.1 
(±0.58) 
19.8 
(±0.63) 
Amphoteri
cin B 
23.7 
(±0.10) 
19.7  
(±0.2) 
28.7  
(±0.20) 
25.4  
(±0.1)  
N.A. N.A. N.A. N.A. 
Ampicillin  N.A. N.A. N.A. N.A. 23.8  
(±0.2)  
32.4 
(±0.30) 
N.A. N.A. 
Gentamicin  N.A. N.A. N.A. N.A. N.A. N.A. 17.3 
(±0.1)  
19.9  
(±0.30)  
The test was done using the diffusion agar technique, well diameter:  6.0 mm  (100 µl was tested), RCMB: Regional 
Center for Mycology and Bio-technology Antimicrobial unit test organisms NA: No activity,  data are expressed in the form 
of mean± SD.  
Minimum inhibition concentration MIC: 
The minimum inhibition concentration and IC50 of four of the newly synthesized products 8b, 11b, 14 and 18 was 
examined against all the employed fungi and bacteria and the results obtained are depicted in the following Tables 2-5. 
These results indicated that the most reactive derivative is compound 14.  
 
Table 2. The minimum inhibition concentration and IC50 of compound 8b 
Sample 
concentration 
(µg/ml) 
A. fumigatus 
Viability % 
S. racemosum 
Viability % 
G. candidum 
Viability % 
C. albicans 
Viability % 
125 86.33 64.35 33.22 49.22 
62.5 100 89.22 49.22 72.44 
31.25 100 100 63.25 88.22 
15.63 100 100 72.14 100 
7.81 100 100 83.52 100 
3.9 100 100 100 100 
1.95 100 100 100 100 
0.98 100 100 100 100 
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0.49 100 100 100 100 
IC 50-MIC ˃125-125 ˃125-62.5 60.8-7.81 98.3-25 
Amphotericin B <0.06-0.015 7.51-1.95 <0.06-0.015 0.5-0.06 
 
Table 2. The minimum inhibition concentration and IC50 of compound 8b 
Sample 
concentration 
(µg/ml) 
S. pneumoniae 
Viability % 
B. subtilis 
Viability % 
P. aeruginosa 
Viability % 
E.coli  
Viability% 
125 42.11 10.32 100 62.58 
62.5 55.44 18.33 100 86.25 
31.25 83.58 42.55 100 100 
15.63 100 66.88 100 100 
7.81 100 82.44 100 100 
3.9 100 100 100 100 
1.95 100 100 100 100 
0.98 100 100 100 100 
0.49 100 100 100 100 
IC50-MIC 88-31.25 15.2-6.25 0-0 ˃100-50 
Ampicillin  <0.06-0.015 <0.06-0.007   
Gentamicin    115-15.63 8.85-1.95 
 
Table 3. The minimum inhibition concentration and IC50 of compound 11b 
Sample 
concentration 
(µg/ml) 
A. fumigates 
Viability % 
S. racemosum 
Viability % 
G. candidum 
Viability % 
C. albicans 
viability % 
125 59.24 31.14 15.36 33.12 
62.5 62.58 54.15 24.12 50.24 
31.25 82.34 64.25 38.12 63.42 
15.63 100 83.58 43.44 77.23 
7.81 100 100 59.24 90.31 
3.9 100 100 84.26 100 
1.95 100 100 100 100 
0.98 100 100 100 100 
0.49 100 100 100 100 
IC50-MIC ˃125-25 73.8-15.63 12.4-3.9 63.4-7.81 
Amphotericin B <0.06-0.015 7.51-1.95 <0.06-0.015 0.5-0.06 
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Table 3. The minimum inhibition concentration and IC50 of compound 11b 
Sample 
concentration 
(µg/ml) 
S. pneumonia 
viability % 
B. subtilis 
Viability % 
P. aeruginosa 
viability % 
E.coli 
Viability% 
125 33.25 17.26 100 36.25 
62.5 56.24 28.66 100 52.44 
31.25 63.25 37.35 100 68.33 
15.63 82.34 49.36 100 89.57 
7.81 100 54.32 100 100 
3.9 100 76.25 100 100 
1.95 100 87.35 100 100 
0.98 100 100 100 100 
0.49 100 100 100 100 
IC50-MIC 79.5-15.63 14.6-1.95 0-0 71.9-15.63 
Ampicillin  <0.06-0.015 <0.06-0.007   
Gentamicin    115-15.63 8.85-1.95 
 
 
Table 4. The minimum inhibition concentration and IC50 of compound 14 
Sample 
concentration 
(µg/ml) 
A. fumigates 
Viability % 
S. racemosum 
Viability % 
G. candidum 
Viability % 
C. albicans 
Viability % 
125 10.12 9.13 8.22 17.25 
62.5 31.66 22.77 19.23 24.16 
31.25 43.22 30.66 28.33 31.28 
15.63 51.66 43.25 32.25 43.28 
7.81 62.44 53.14 46.77 62.55 
3.9 73.25 62.11 56.67 83.44 
1.95 88.22 76.33 71.72 100 
0.98 100 86.22 80.25 100 
0.49 100 100 100 100 
IC50-MIC 18.7-1.95 10.3-0.98 6.53-0.98 12.9-3.9 
Amphotericin B <0.06-0.015 7.51-1.95 <0.06-0.015 0.5-0.06 
 
 
 
 
 
 
 
 
 
 
    ISSN 2321-807X 
2763 | P a g e                                                   S e p t e m b e r  1 9 ,  2 0 1 4  
Table 4. The minimum inhibition concentration and IC50 of compound 14 
Sample 
concentration 
(µg/ml) 
S. pneumonia 
Viability % 
B. subtilis 
Viability % 
P. aeruginosa 
Viability % 
E. coli  
Viability% 
125 11.63 10.22 90.33 20.34 
62.5 36.25 25.76 100 30.66 
31.25 49.28 40.67 100 39.28 
15.63 57.99 59.27 100 50.66 
7.81 69.25 66.34 100 72.29 
3.9 78.39 74.26 100 83.42 
1.95 89.44 86.25 100 100 
0.98 100 93.22 100 100 
0.49 100 100 100 100 
IC50-MIC 30-1.95 23.4-0.98 ˃125-125 16.5-3.9 
Ampicillin  <0.06-0.015 <0.06-0.007   
Gentamicin    115-15.63 8.85-1.95 
 
 
Table 5. The minimum inhibition concentration and IC50 of compound 18 
Sample 
concentration 
(µg/ml) 
A. fumigates 
Viability % 
S. racemosum 
Viability % 
G. candidum 
Viability % 
C. albicans 
Viability % 
125 53.44 20.73 7.38 62.57 
62.5 76.25 40.66 13.97 86.42 
31.25 82.44 59.42 49.35 100 
15.63 100 73.25 58.64 100 
7.81 100 86.44 68.25 100 
3.9 100 100 83.25 100 
1.95 100 100 100 100 
0.98 100 100 100 100 
0.49 100 100 100 100 
IC50-MIC ˃125-31.25 46.9-7.81 30.2-3.9 ˃125-62.5 
Amphotericin B <0.06-0.015 7.51-1.95 <0.06-0.015 0.5-0.06 
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Table 5. The minimum inhibition concentration and IC50 of compound 18 
Sample 
concentration 
(µg/ml) 
S. pneumonia 
Viability % 
B. subtilis 
Viability % 
P. aeruginosa 
Viability % 
E. coli  
Viability % 
125 16.25 18.37 87.32 22.36 
62.5 20.67 33.26 100 35.68 
31.25 50.67 49.27 100 53.26 
15.63 59.25 62.58 100 78.32 
7.81 73.44 70.25 100 86.34 
3.9 91.34 79.34 100 89.16 
1.95 100 89.25 100 93.25 
0.98 100 100 100 100 
0.49 100 100 100 100 
IC50-MIC 31.9-3.9 30.4-1.95 ˃125-125 37-1.95 
Ampicillin  <0.06-0.015 <0.06-0.007   
Gentamicin    115-15.63 8.85-1.95 
 
Conclusion: 
In the present paper, we described a facile method for synthesis of tetra- and pentacyclic compounds via coupling reaction 
of a number of exocyclic enaminones with some heterocyclic diazonium salts. The tetra-and pentacyclic compounds were 
obtained either by in situ dehydrative cyclization of the initially formed hydrazones or by thermal treatment of the 
respective hydrazones with glacial acetic acid. Also, some of the newly synthesized products were tested against some 
fungi and bacteria and the results obtained indicate that all the tested compounds have high activity against most of the 
employed microorganisms. Moreover, compound 14 showed promising results since it has a higher potency against the 
fungus Syncephalastrum racemosum than the standard employed fungicide Amphotericin B. 
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